Incyte Corp.

Strong top-line start + reaffirmed full-year guidance (good) - Q1’26 total revenue $1.27B (+21% YoY); net sales $1.10B (+20% YoY), with sales growth across every marketed product and in both U.S. and international. - Jakafi $758M (+7% YoY): prescriptions +6%, broad indication growth (MF/PV/GVHD) and stable prescriber base + strong formulary coverage, supporting the Jakafi XR launch. - Core business ex-Jakafi up +63% YoY, driven by hematology/oncology/immunology growth; company said this ex-Jakafi business could reach ~$3–$4B by 2030. - Financials: GAAP R&D $516M (+18% YoY); GAAP SG&A $328M (+1% YoY) (operating leverage improving). - Full-year 2026 guidance reiterated: total net sales $4.77B–$4.94B (+10%–13% YoY), Jakafi $3.22B–$3.27B, Opzelura $750M–$790M, hematology/oncology $800M–$880M; GAAP R&D+SG&A $3.495B–$3.675B. - Cost of sales ~9% of net sales (stable).

Jakafi XR pathway is a major near-term growth driver (good + execution risk) - FDA expected approval and launch mid-2026 for Jakafi XR (management: “sales bridge” and future growth engine). - Company’s critical near-term focus: securing adequate formulary coverage for XR over the 12 months post-launch. - Forward estimate: XR could reach 10%–30% of Jakafi’s business by 2029 (high upside if payer/formulary execution works; sensitive to managed care dynamics).

Immunology: povo (oral JAK1) and vitiligo data are key catalysts (big opportunity) - FDA accepted NDA for povorcitinib in moderate-to-severe HS (submitted ahead of schedule); management positions povo as a major growth driver as the first FDA-approved oral anti-inflammatory for HS (HS affects >300k in U.S.). - Povorcitinib Phase III vitiligo (nonsegmental) topline positive: - Expected regulatory application in first half of 2027, with approval/launch anticipated in early 2027 (per call narrative). - Commercial “continuum” strategy: management explicitly argues the market can be “medicalized” and that Incyte can cover vitiligo from smaller BSA to larger BSA using both Opzelura (topical) and povo (oral). - Surprising/positive: they highlight patient segmentation (Mohamed’s framing) — Opzelura targeted to ~BSA <5 and 5–10, while povo targets BSA >10; plus “topical to oral” could improve treatment adherence/sequence.